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ABSTRACT
A review of the pharmacological aspects of greatest relevance in relation to the monitoring of
itraconazole serum levels is presented in this article. The main causes of pharmacokinetic variability,
e.g., poor aqueous solubility, the presystemic ﬁrst-pass effect with the involvement of transporters such
as P-glycoprotein, the high extent of metabolism mediated by the CYP450 system and a high probability
of pharmacological interactions, are documented and discussed. The pharmacokinetic–pharmacody-
namic criteria used to optimise antibiotic therapy, as well as their application to antifungal drugs, are
also discussed. Data concerning the breakpoints established for the minimum serum concentrations of
itraconazole are included, and the most relevant justiﬁcations for drug monitoring are cited.
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INTRODUCTION
It is known that the intrinsic activity is a charac-
teristic required for a product to become a drug.
Nevertheless, the activity of a drug does not
sufﬁciently guarantee its safety and efﬁcacy for
pharmacological treatments. In the particular ﬁeld
of anti-infective therapy, many chemical products
showing high or even very high activity (potency)
against several pathogens of clinical interest also
present serious difﬁculties in their use as thera-
peutic agents in clinical practice. The physico-
chemical or biological properties related to their
kinetic or safety proﬁles, and problems related to
industrial manufacturing, are among the several
limitations [1].
Regardless of the clinical circumstances affect-
ing the patient, the outcome of a treatment
depends on both the pharmacokinetics and
pharmacodynamics of the anti-infective drug
administered, the former being conditioned
by absorption, distribution, metabolism and
excretion processes. Characterisation of the kinetic
proﬁle of a drug is one of the main goals during
the clinical development of new molecules, and
this type of information is essential in establishing
the pharmaceutical form, the administration route
and the dosage schedules. Changes affecting the
pharmacokinetic processes lead to variations in
plasma concentrations as well as in the exposure
of the target site to the drug; consequently, these
modiﬁcations may ﬁnally affect the safety and
efﬁcacy of the treatment. Pharmacodynamics
relate to the intrinsic activity and potency of the
product against a particular organism, the mini-
mum inhibitory concentration (MIC) being the
parameter most widely used as the pharmacody-
namic variable, although additional concepts, e.g.,
the post-antibiotic effect, the post-b-lactamase
inhibitor effect or the margin for selection of
resistance, have recently been incorporated in
studies performed with anti-infective agents [2–4].
In recent years, pharmacokinetic–pharmaco-
dynamic (PK–PD) analysis applied to infectious
diseases has undergone important advances,
leading to the consideration of some PK–PD
parameters as response surrogate variables.
This type of analysis combines both pharmaco-
kinetic and pharmacodynamic information about
the antimicrobial agent. The area under the
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concentration–time curve (AUC), being the most
representative parameter of exposure to a drug,
the maximum plasma concentration (Cmax) and
the fraction of dosage interval for which drug
levels remain above the MIC are the three phar-
macokinetic parameters most widely used, the
MIC being the only pharmacodynamic parameter
currently used for this purpose. Although PK–PD
analysis is being undertaken to improve pharma-
cological treatment with several groups of antibi-
otics, e.g., aminoglycosides, ﬂuoroquinolones,
b-lactams and glycopeptides, this strategy is
rarely applied to antifungal agents [5].
The clinical response observed with a drug after
the administration of a particular dose may be
very different among different patients and may
even differ in the same patient during treatment.
Thus, a given dose might lead to inefﬁcacy,
therapeutic effect or toxicity when used in clinical
practice, particularly for drugs with a narrow
therapeutic window. This inter- and intra-individ-
ual variability is caused by several factors affecting
the relationship between the dose administered
and the intensity or duration of pharmacological
effects. Such variability has both pharmacokinetic
and pharmacodynamic components, the latter
being the most difﬁcult to characterise [6].
Regarding pharmacokinetics, inter-individual
variability has long been recognised and justiﬁes
the use of different dosage patterns in different
population groups, e.g., paediatric, geriatric or
renal-impaired patients, among others. Intra-indi-
vidual variability, however, is less well-under-
stood and is often ignored as being responsible
for unexpected modiﬁcations during a given
therapeutic regimen. Systematic monitoring of
serum concentrations performed in hospital cen-
tres for several drugs has revealed the signiﬁ-
cance of these modiﬁcations, which may lead to
erratic effects on some occasions [7]. Genetic
factors related to drug receptors, binding
enzymes, biological transporters (MDR1, P-glyco-
protein, etc.) or enzymic systems involved in drug
metabolism, together with the pharmacological
interactions and physiological or pathological
factors, mainly explain the differences observed
in the pharmacokinetic proﬁle of a drug. All these
factors may affect the absorption, distribution,
metabolism and excretion processes [8], eliciting
changes in the amount and ⁄ or absorption rate
(bioavailability), body access (distribution vol-
ume) or elimination capacity (plasma clearance).
Fig. 1 illustrates the inﬂuence of changes in drug
clearance produced by some of the above factors
on the pharmacological response. The graph
includes the kinetic proﬁles simulated for a
particular anti-infective drug in two hypothetical
patients showing different drug clearance (100
and 50 mL ⁄min). A wider systemic exposure to
the antimicrobial agent (higher AUC value) is
observed in the case of lower drug clearance.
Since the AUC ⁄MIC is correlated with clinical
response (microbiological cure, clinical outcome,
etc.), the differences in the AUC values observed
for the two cases will lead to different responses
to the same treatment.
Pharmacological interactions are another rele-
vant source of pharmacokinetic or pharmacody-
namic variability, and the consequences may be
inefﬁcacy or toxicity in the case of drugs with a
narrow therapeutic window [9]. The adverse
reactions caused by pharmacological interactions
may result from the drug’s side-effects appear-
ance at a higher incidence and severity or may be
new adverse effects not related to the drug when
used alone. The former are likely to be due to
alterations in any particular pharmacokinetic
process that leads to a signiﬁcant increase of drug
levels in serum and body tissues, causing effects
similar to those produced by acute or chronic
intoxication as a consequence of overdosing. A
different situation appears when the associated
drugs bind to the same receptors or biological
systems, in which case pharmacodynamic inter-
actions will be more likely to occur.
Fig. 1. Kinetic proﬁles simulated for a single dose of a
given anti-infective drug in two hypothetical patients
showing different drug clearance levels (100 and
50 mL ⁄min). The differences in the AUC values observed
for the two cases will lead to different responses to the
same treatment.
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Interactions related to the enzymic systems
involved in drug metabolism, mainly CYP2C9,
CYP3A4, CYP2D6 and CYP2C19, are among the
most relevant pharmacokinetic interactions. The
enzymic inhibition that appears when two or
more drugs with afﬁnity for the same system are
associated is dose-dependent, with a high degree
of selectivity, and it is generally reversible. Most
reversible inhibitors are molecules that have
nitrogen, imidazole, pyridine or quinolone
groups in their chemical structure. Molecules of
this type bind to the prosthetic group and the
lipophilic region of the enzyme to block enzymic
activity. This explains why the potency of inhib-
itors is dependent on their lipophilicity and the
intensity of binding to the prosthetic group on the
enzymic system [10–13].
The clinical relevance of enzymic inhibition
depends on different factors, the therapeutic
margin of the drug involved being the most
important. For example, patients receiving anti-
coagulants, antidepressants and immunosup-
pressive or cardiovascular agents have a higher
risk of side-effects than those receiving drugs
with a broader therapeutic range. Despite phar-
macological interactions being well-controlled in
most cases, they may lead to life-threatening
conditions on some occasions. In order to make a
proper prediction of the consequences of inter-
actions related to the metabolism of a drug, it
is necessary to identify the enzymic routes
involved in the process and to establish the
contribution of each enzymic system. In some
cases, the same enzyme produces several meta-
bolic transformations, while in other cases, sev-
eral enzymic systems may be involved in a
single reaction [14–17]. Adverse reactions pro-
duced by pharmacological interactions should be
carefully considered, and strategies such as
monitoring of drug levels and dosage individu-
alisation should be implemented in order to
avoid these unwanted effects. A wide knowledge
of the pharmacological characteristics of the drug




The pharmacokinetics of itraconazole have been
extensively studied and are well-documented in
several reviews [18–24]. Only the most relevant
points in relation to therapeutic drug monitoring
(TDM) are addressed here.
Itraconazole is a highly lipophilic molecule. It is
a slightly acidic salt (pKa ¼ 3.7), and hence is
ionisable only at very low pH values. It is also
poorly soluble in water, with an aqueous solubil-
ity close to 1 ng ⁄mL at pH 7 and slightly higher
than 4 ng ⁄mL at pH 1. These characteristics make
the oral absorption of itraconazole difﬁcult when
it is administered as capsules. For this type of
formulation, reduced bioavailability was
observed when the drug was administered under
fasting conditions, particularly in patients show-
ing low gastric acidity. These ﬁndings were
associated with the low solubility of itraconazole,
which is the aspect limiting the absorption pro-
cess. The administration of capsules together with
food, as well as the co-administration of acidic
ﬂuids such as cola drinks, were strategies used to
overcome the problem [25,26]. Gastrointestinal
absorption is limited by solubility (responsible for
the concentration of drug able to pass through
membranes and also for the rate of dissolved
molecules appearing at the absorption site), by the
acidic ⁄ basic character (determining the ionised
fraction in solution at a given pH), by the
lipophilicity (controlling the partition coefﬁcient
between the aqueous and lipophilic phases of
body tissues) and by the permeability (determin-
ing the ability of molecules to pass through
membranes).
The Biopharmaceutical Classiﬁcation System
proposed by Amidon et al. [27] groups drugs
according to their aqueous solubility and their
permeability. This classiﬁcation was ﬁrst accepted
by the FDA, and then by the European Agency for
the Evaluation of Medical products (EMEA) in
1998, and it is now being used efﬁciently, not only
during the preclinical development of new drugs,
but also for the planning of bioavailability assays
according to the in-vitro ⁄ in-vivo data relation-
ships, and for the design of new therapeutic
forms.
According to the Biopharmaceutical Classiﬁca-
tion System, itraconazole belongs to class II,
which includes molecules with low solubility
and high permeability, for which the dissolution
rate is the factor limiting absorption. In this
situation, changes in the molecular structure
leading to chemical species with higher water
solubility or modiﬁcations in the pharmaceutical
dosage form are the most frequent strategies for
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increasing drug bioavailability, the formation of
complexes being one method that can be used for
this purpose. Complex formation may be deﬁned
as the reversible association of substrate and
ligand molecules to form a new chemical species
known as a complex, with a deﬁned molecular
ratio, which has physico-chemical properties that
in many cases may be very different from those of
their components (substrates). Among the differ-
ent types of complexes, it is worth mentioning the
so-called inclusion complexes, which are pro-
duced by an interaction at the molecular level
between two types of compound; one of them acts
as the ‘host’, being able to take into its structure
another compound called the ‘guest’ [28]. Cyclo-
dextrins (CDs) are among the host compounds,
and are currently the most widely used for this
purpose, due to their favourable characteristics,
which include adequate size, good stability and
reduced side-effects. When the CD–drug complex
comes into contact with an aqueous medium, the
complex dissociates and the guest molecule is
released. The dissociation rate constant of the
complex determines the amount of free drug, and
hence, the absorption rate is limited by this factor
[29]. Moreover, the CD–drug complex may have
higher chemical stability, solubility and bioavail-
ability than the free drug [29].
An inclusion complex formed by itraconazole
and a particular type of CD (2-hydroxypropyl-
b-cyclodextrin) at a molecular ratio of 1:3 signiﬁ-
cantly modiﬁes the solubility of the antifungal
agent, producing an increase in the oral bioavail-
ability of the drug [30]. The synthesis of this
inclusion complex facilitates the formulation of
itraconazole as an oral solution, as well as a
parenteral preparation for intravenous adminis-
tration [19,31]. The oral solution of itraconazole
has a more favourable bioavailability than the
capsule form [22]. A comparative study revealed
a 37% increase in the relative bioavailability of the
former formulation as compared to the latter.
More recent studies have shown that the absorp-
tion of the oral solution of CD–itraconazole is
increased in the absence of food, providing an
additional advantage for at-risk patients. Phar-
macokinetic assays have revealed that adminis-
tration of the oral solution with no food leads to
an increase in the AUC as well as in the Cmax
values. In sum, the administration of the oral
solution containing the CD–itraconazole complex
under fasting conditions produces a 30% increase
in absorption, compared to administration of this
formulation with food [32]. Although tolerance to
CDs is high, it must be taken into account that
these compounds may accumulate in renal-
impaired patients because of their renal excretion
[19].
Itraconazole is widely distributed throughout
the body, this process being highly dependent on
the physico-chemical properties of the drug, with
a reported apparent distribution volume of
10.7 L ⁄kg. It is highly bound to serum proteins,
mainly to serum albumin, and it has a bound
fraction of 99.8%. In some body tissues, e.g., skin,
lungs, muscle and liver, very high concentrations
of itraconazole and ⁄ or its metabolites are found
[19,20,22,26,33]. Data concerning the disposition
of the drug after inhalation have conﬁrmed that
the parent drug and its hydroxy metabolite reach
tissue concentrations higher than simultaneous
plasma levels [34].
Itraconazole is extensively biotransformed in
the organism and more than 30 metabolites have
been identiﬁed. The major metabolic route is
mediated by the CYP450 system, the main isoen-
zymes involved in the metabolism of the azole-
type antifungal agents being the following:
CYP3A4 (itraconazole, ketoconazole, voriconaz-
ole, ﬂuconazole) and CYP2C9 or CYP2C19
(ﬂuconazole, ketoconazole, voriconazole). For
itraconazole, the major metabolite is the hydroxy
derivative, which shows an antifungal activity
similar to that of the parent drug according to
in-vitro studies. The concentrations of this deriv-
ative are about 1.5–2 times the corresponding
levels of the parent drug [19,22].
An elimination half-life of 20 h has been report-
ed for itraconazole after its administration as a
single dose of 200 mg. Nevertheless, this para-
meter increases to 30 h under steady-state condi-
tions as a consequence of saturation of the
metabolic processes [35].
The pharmacokinetics of itraconazole have
been studied in different population groups. No
signiﬁcant modiﬁcation of the pharmacokinetic
processes has been found in renal-impaired
patients. Accordingly, modiﬁcations in the dosage
schedules would not be necessary in this type of
patient, although administration of the drug is not
recommended for individuals with a creatinine
clearance under 30 mL ⁄min, probably because of
the impaired renal excretion of metabolites and
CD, with the corresponding accumulation in this
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situation [36,37]. Modiﬁcations in the absorption
and elimination of itraconazole, however, have
been observed in cirrhotic patients, and dosage
individualisation is recommended for this popu-
lation group [38].
Itraconazole is a potent enzymic inhibitor
[18,39,40] and therefore some precautions have
to be taken when it is associated with other drugs.
Clearance alterations due to enzymic inhibition or
induction directly affect serum plasma levels, the
AUC value and even bioavailability when enzy-
mic systems are involved in the absorption
process. Fig. 2 includes the serum concentration
proﬁles simulated for a drug undergoing meta-
bolism administered alone and associated with an
enzymic inhibitor. As a consequence of the
decrease in clearance, an increase in serum levels
above the maximum tolerated concentrations may
occur for drugs with a narrow therapeutic win-
dow [40,41]. In the case of itraconazole being
administered in association with other drugs with
a capacity for enzymic induction or inhibition, the
interaction may affect the serum concentrations of
the antifungal agent. Accordingly, rifampicin,
rifabutin, diphenylhydantoin and carbamazepine,
all well-known as enzymic inducers, reduce the
serum levels of itraconazole, while inhibitor
drugs such as clarithromycin, erythromycin, rito-
navir and indinavir lead to an increase in itrac-
onazole levels [20,42].
The potential effects of itraconazole on other
drugs, as a consequence of its high enzymic
inhibitory capacity, should also be borne in mind,
particularly for immunosuppressive agents, oral
anticoagulants, statins, and anti-retroviral or
cytotoxic products [43–45]. Data from our
laboratory conﬁrm this statement, since it was
found that the half-life of sirolimus was increased
from 62 to 602 h when it was associated with
itraconazole. Also, cyclosporin undergoes a rele-
vant interaction with itraconazole, and its associ-
ation with this drug was incorporated as a
categorical co-variable to estimate the clearance
of the immunosuppressive agent in a population
model for cyclosporin in transplant recipients
[47]. Additionally, itraconazole and several other
products that inhibit the liver CYP450 system or
P-glycoprotein (ﬂuconazole, voriconazole nifedi-
pine, etc.) undergo interactions with vincristine
and cyclophosphamide that affect their metabo-
lism and lead to an increase in the toxicity of these
compounds [47–49].
TDM should be supported by analytical, PK–
PD, clinical and pharmaco-economic criteria. The
monitoring of serum concentrations of some
drugs has constituted routine practice in many
hospitals for the last 25 years, although, in fact,
this practice was initiated much earlier (1960) in
some centres. The initial aim of TDM was to
individualise dosage schedules with a view to
improving clinical outcomes, but improvements
in the safety proﬁles of drugs showing potential
toxicity, e.g., aminoglycosides, glycopeptides or
antiepileptic drugs, rapidly became the main goal
of TDM. Accordingly, this procedure provides an
excellent tool for control of pharmacological
treatments, patient protection and improvement
in the safety of drugs [41]. Currently, the devel-
opment of TDM programmes is restricted to
situations fulﬁlling several requirements related
to analytical, pharmacological, clinical and eco-
nomic issues.
The implementation of a TDM programme ﬁrst
requires the existence of an analytical technique
that shows the appropriate criteria of accuracy,
speciﬁcity, sensibility and efﬁciency. In recent
years, several techniques for the quantiﬁcation of
itraconazole that fulﬁl the above requirements
have been developed and reported [50]. Most of
them are techniques involving chromatography,
capillary electrophoresis and mass spectropho-
tometry, all of these being complicated for imple-
mentation in the clinical setting. Prompted by the
interest in monitoring itraconazole, we have
developed a chromatographic technique using
ﬂuorescence detection. This analytical method has
been validated and it allows us to accurately
Fig. 2. Serum concentration proﬁles simulated for a mul-
tiple dosage regimen for a drug administered alone and in
association with an enzymic inhibitor. MTC, maximum
tolerated concentration.
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determine serum concentrations of itraconazole
and its hydroxy metabolite within a run time of
less than 8 min, with quantiﬁcation limits of 50
and 25 ng ⁄mL for the parent drug and metabolite,
respectively. In brief, the analytical method is as
follows: serum samples (500 L) are subjected to a
single liquid–liquid extraction process with
diethyl ether in basic medium. The extractive
phase is mixed with the eluent phase (acetonitri-
le ⁄water, 55:45, with tri-ethanol amine adjusted to
pH 3 with orthophosphoric acid). Following this,
it is injected into the chromatographic equipment
(Hewlett Packard 1050; ﬂuorescence detector
Shimadzu RF-10AXL; kexc ¼ 260 nm; kemiss ¼
365 nm) at a ﬂow rate of 1.5 mL ⁄min. It is
important to make sure that the analytical proce-
dure has been properly validated, and inter-
ference with additional drugs used in
polytherapy has to be avoided.
Regarding PK–PD criteria, antifungal agents
may be assembled using the same classiﬁcation
system as that used for antibiotics [51]. Accord-
ingly, they can be allocated to class I, II or III,
depending on their killing mechanism pattern.
Class I would include drugs showing a concen-
tration-dependent pattern together with a rele-
vant post-antifungal effect such as amphotericin B
and caspofungin. For this group, the Cmax ⁄MIC
and AUC ⁄MIC are the response surrogate varia-
bles. Flucytosine would be included within class
II, which includes products with a time-depend-
ent antifungal effect and reduced post-antifungal
effect, the surrogate variables being, in this case,
T>MIC and AUC ⁄MIC. Finally, class III would
include the azole-type antifungal agents, itra-
conazole being among them. For this group, a
time-dependent effect, together with a variable
post-antifungal effect, is observed. As for class II,
AUC ⁄MIC and T>MIC seem to be the parameters
best related to response. According to these
considerations, the time needed for minimum
serum concentrations (Cmin) to be reached has
been selected as the sampling time for monitoring
itraconazole levels. This means that blood should
be withdrawn immediately before administration
of the next dose (at the end of a dosage interval).
In order to achieve maximum efﬁcacy with
itraconazole treatments, the concentration at this
sampling time must be above the MIC value
established for the infecting pathogen.
The existence of a well-deﬁned therapeutic
range is another essential requirement for
performing TDM. This is necessary for decision-
making and optimisation of dosage schedules. In
the particular case of itraconazole, early studies
performed in vitro and with laboratory animals,
to deﬁne the relationship between serum con-
centrations and antifungal activity, revealed that
more than 99.6% of 750 strains of dermatophytes
were inhibited by concentrations of 1000 ng ⁄mL
[52]. Data from another study [53] using an
experimental model with infection produced by
Aspergillus fumigatus showed a sigmoid relation-
ship between serum concentrations of itraconaz-
ole and antifungal activity. Cmin values above
600 ng ⁄mL were related to maximum inhibitory
activity, and Cmin values lower than this were
linked to lower activity. Several clinical stud-
ies have established a breakpoint for Cmin of
500 ng ⁄mL, which is related to a lower incidence
of massive fungal invasion [24,54,55]. Neverthe-
less, other clinical studies failed to reach the same
conclusion, probably due to the difﬁculty of
setting up homogeneous study groups
[54,56,57]. A meta-analysis was performed in
order to establish the relationship between the
efﬁcacy of itraconazole for the prophylaxis of
fungal infections in neutropenic patients and the
dose [58]. The authors, however, did not use
the dose administered but what they called the
bioavailable daily dose (BDD), which was
deﬁned as the product of the dose administered
(D) and the absolute bioavailability of the for-
mulation (F). Patients were divided into two
groups according to the F value of the formula-
tion administered (F ¼ 22% for capsules and
F ¼ 55% for oral solution). The group receiving a
BDD of 200 mg (oral solution) showed a lower
incidence of fungal infections than the group
receiving a BDD of 100 mg (capsules). These
results agree with data from the above-men-
tioned studies, relating better efﬁcacy to higher
Cmin values. The authors of the meta-analysis
suggested a breakpoint for the BDD of 200 mg,
which is equivalent to 400 mg of itraconazole
administered as an oral solution [58].
Nonetheless, the current data concerning itrac-
onazole are insufﬁcient to deﬁne a therapeutic
window for this drug, although a value of
500 ng ⁄mL for Cmin has been accepted as the
efﬁcacy breakpoint for this drug. As the active
hydroxy metabolite is present in serum at con-
centrations of 1.5–2-fold the corresponding levels
of the parent drug, Cmin values of itraconazole
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above the selected breakpoint mean that the Cmin
for total active compounds (parent drug plus
active metabolite) is higher than the MIC values
for pathogens responsible for most fungal infec-
tions [59,60].
Some dosage schedules based on the adminis-
tration of a loading dose have been reported to
achieve steady-state levels within the ﬁrst days of
treatment with itraconazole. Nevertheless, TDM
could offer an additional strategy for attaining the
optimum dosage schedule in the shortest period
of time. The dosage patterns established for
steady-state levels to be reached rapidly are as
follows. For the intravenous route, 200 mg ⁄ 12 h
should be administered for 2 days, followed by a
maintenance dose of 200 mg daily. When the oral
route is chosen, 200 mg ⁄ 12 h of the oral solution
should be administered, followed by monitoring
of serum levels on day 7 of treatment. If the
concentration measured has the recommended
value, the same treatment can be maintained. In
the case of the desirability of achieving steady-
state levels within the ﬁrst 48 h by oral adminis-
tration because the intravenous route is not
indicated, the treatment should be initiated with
the oral solution at 800 mg ⁄ 12–24 h for 2 days
(loading dose), followed by 200 mg ⁄ 12 h. TDM of
itraconazole is of particular interest in the follow-
ing cases: when new drugs are associated with it,
in the event of possible unknown pharmacoki-
netic interactions; when non-compliance with the
prescribed treatment is suspected; or in cases of a
high probability of low bioavailability. This clin-
ical practice is also recommended during chemo-
therapy cycles and immediately after the end of
such treatments [60].
When serum levels of itraconazole are monit-
ored, modiﬁcations to the dosage schedule are
recommended in the following situations.
1. When the Cmin determined after 3 days of
treatment with 200 mg ⁄ 12 h is above 500
ng ⁄mL but lower than 2000 ng ⁄mL, the dosage
interval should be extended to 24 h.
2. When the Cmin determined after 3 days of
treatment with 200 mg ⁄ 12 h is above 2000
ng ⁄mL, intravenous administration should be
stopped and the oral route must be used, if
tolerated by the patient.
3. When the Cmin determined after 3 days of
treatment with 200 mg ⁄ 12 h is below 500
ng ⁄mL, the same intravenous pattern should
be maintained.
As mentioned above, we have implemented a
TDM program for itraconazole, with a total of 54
patients and 122 serum determinations being
included to date. The mean values of Cmin
deermined for itraconazole and its hydoxy meta-
bolite are 1237.57 ± 990.07 ng ⁄mL and 2087.49 ±
1542.35 ng ⁄mL, respectively (unpublished data).
The high variability in these values and also the
low percentage (54.1%) of the Cmin values within
the 500–2000 ng ⁄mL range should be noted.
Among the rest, 25.4% are below 500 ng ⁄mL
and 20.5% above 2000 ng ⁄mL. Although the data
available are too limited for deﬁnitive conclusions
to be drawn, this preliminary information points
to a signiﬁcant number of patients with Cmin
values below the recommended breakpoints
when they receive the standard doses. These
ﬁndings support the interest in TDM for optim-
ising treatment with itraconazole.
In summary, the most relevant justiﬁcations for
the monitoring of serum concentrations of itrac-
onazole are:
1. Low and erratic bioavailability. Like other
drugs with poor water solubility, itraconazole
is not well-absorbed after oral administration,
leading to highly variable absorption extent
and rates and, consequently, to differences in
serum levels as well as AUC values. The
involvement of P-glycoprotein in the oral
absorption of itraconazole may be another
reason for the high variability observed in the
bioavailability of this drug, since this deter-
mines the presystemic ﬁrst-pass effect [61].
Although the new oral solution improves
absorption and reduces variability, the bio-
availability of itraconazole cannot be consid-
ered to be optimal.
2. Absorption processes being inﬂuenced by sev-
eral factors such as pathologies and chemo-
therapy. Many clinical circumstances modify
the permeability of gastrointestinal membranes
and lead to changes in the amount and rate of
drug absorption. Neutropenic status in AIDS
patients or transplant recipients are two exam-
ples of factors affecting the oral bioavailability
of itraconazole.
3. Dose-dependent pharmacokinetics. In the case
of itraconazole, non-linear kinetics have been
reported and documented [20]. Consequently,
increases in dosage do not produce propor-
tional increases in serum concentrations. This
has been attributed to the limited metabolic
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capacity of the organism [35] and also to the
involvement of biological transporters such as
P-glycoprotein in the presystemic ﬁrst-pass
effect [61].
4. Poor correlation between the dose admin-
istered and serum levels. Because of the
high variability in the values of pharma-
cokinetic parameters, the same dose may
lead to very different concentration–time
proﬁles in different patients, and even to
differences during the treatment of a single
patient.
5. High probability of interactions with other
drugs that are substrates of CYP450. Inhibitors
or inducers of this enzymic system may affect
the metabolism of itraconazole and hence
increase or decrease, respectively, the serum
levels of the antifungal agent. It should be
noted that itraconazole, as a potent enzymic
inhibitor, might also modify the serum proﬁle
of co-administered drugs that are metabolised
through the above-mentioned CYP450 system,
particularly when these drugs have a narrow
therapeutic window.
6. Additional strategy for compliance control
among patients receiving oral treatment.
Although the oral route is more convenient
for patients at home, the risk of non-compli-
ance is still high and TDMmay be a method for
gaining insight into patient compliance. The
serum concentration ⁄dose ratio is used as a
measure of the degree of compliance.
7. Optimisation of hospital public health
resources. Nowadays, implementation of
health technologies and ⁄ or strategies should
be supported by efﬁciency and efﬁcacy cri-
teria. Pharmaco-economic studies include ana-
lysis and evaluation of beneﬁts ⁄ risk vs. the
costs of health interventions in which the use
of drugs is involved. Cost-efﬁciency studies
provide the proper support for decision-
making about the selection of drugs and other
different health-oriented procedures. Recent
assays have shown that the cost of invasive
fungal infections may lie between 22 197 and
31 200 US$ per episode, while the cost of the
oral drug (400 mg ⁄day) is only about 16 US$
per day. Additional pharmaco-economic stud-
ies would be necessary to evaluate the global
economic impact of the prophylaxis of fungal
infections on public health-related costs.
Recently, Buchkowsky et al. have reported
the interest in and possible limitations of
TDM of itraconozole, highlighting the rele-
vance of this clinical strategy for immuno-
suppressed patients [60].
CONCLUSIONS
Itraconazole is an antifungal agent with an
interesting pharmacodynamic proﬁle. Its clinical
usefulness in the prophylaxis and treatment of
fungal infections has been proven and well-
documented. However, owing to its pharmaco-
kinetic proﬁle, careful control of patients
receiving treatment with this drug is recom-
mended. The new oral solution, based on the CD
inclusion complex, improves the bioavailability
and facilitates patient compliance with treatment
outside hospital because of the possibility of
once-daily administration. Since the drug is
metabolised by the CYP450 enzymic system,
there is a high probability of interactions with
other drugs that use the same metabolic route.
Additionally, itraconazole is a potent enzymic
inhibitor and may therefore modify the kinetic
proﬁle of co-administered drugs that are sub-
strates of the CYP450 system. The pharmacoki-
netic variability of itraconazole and its clinical
consequences may be controlled by the imple-
mentation of a proper TDM programme.
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